Isoform-specific Potentiation of Stem and Progenitor Cell Engraftment by Aml1/runx1 Methods and Findings

Funding: The authors received no specific funding for this study. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med 4(5): e172. distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background AML1/RUNX1 is the most frequently mutated gene in leukaemia and is central to the normal biology of hematopoietic stem and progenitor cells. However, the role of different AML1 isoforms within these primitive compartments is unclear. Here we investigate whether altering relative expression of AML1 isoforms impacts the balance between cell self-renewal and differentiation in vitro and in vivo. The human AML1a isoform encodes a truncated molecule with DNA-binding but no transactivation capacity. We used a retrovirus-based approach to transduce AML1a into primitive haematopoietic cells isolated from the mouse. We observed that enforced AML1a expression increased the competitive engraftment potential of murine long-term reconstituting stem cells with the proportion of AML1a-expressing cells increasing over time in both primary and secondary recipients. Furthermore, AML1a expression dramatically increased primitive and committed progenitor activity in engrafted animals as assessed by long-term culture, cobblestone formation, and colony assays. In contrast, expression of the full-length isoform AML1b abrogated engraftment potential. In vitro, AML1b promoted differentiation while AML1a promoted proliferation of progenitors capable of short-term lymphomyeloid engraftment. Consistent with these findings, the relative abundance of AML1a was highest in the primitive stem/progenitor compartment of human cord blood, and forced expression of AML1a in these cells enhanced maintenance of primitive potential both in vitro and in vivo. Conclusions These data demonstrate that the ''a'' isoform of AML1 has the capacity to potentiate stem and progenitor cell engraftment, both of which are required for successful clinical transplantation. This activity is consistent with its expression pattern in both normal and leukaemic cells. Manipulating the balance of AML1 isoform expression may offer novel therapeutic strategies, exploitable in the contexts of leukaemia and also in cord blood transplantation in adults, in whom stem and progenitor cell numbers are often limiting.

[1]  Carsten Peterson,et al.  Transcriptional Dynamics of the Embryonic Stem Cell Switch , 2006, PLoS Comput. Biol..

[2]  G. Swiers,et al.  Genetic regulatory networks programming hematopoietic stem cells and erythroid lineage specification. , 2006, Developmental biology.

[3]  F. Buchholz,et al.  AML1 deletion in adult mice causes splenomegaly and lymphomas , 2006, Oncogene.

[4]  J. Wagner,et al.  Umbilical cord blood transplantation and banking. , 2006, Annual review of medicine.

[5]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[6]  H. Tagawa,et al.  Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma , 2005, Clinical Cancer Research.

[7]  Tariq Enver,et al.  Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. , 2005, Blood.

[8]  Karen Blyth,et al.  The runx genes: gain or loss of function in cancer , 2005, Nature Reviews Cancer.

[9]  J. Downing,et al.  Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. , 2004, Blood.

[10]  J. Kutok,et al.  Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. , 2004, Blood.

[11]  B. Sorrentino.  Clinical strategies for expansion of haematopoietic stem cells , 2004, Nature Reviews Immunology.

[12]  Elaine Dzierzak,et al.  GATA-2 Plays Two Functionally Distinct Roles during the Ontogeny of Hematopoietic Stem Cells , 2004, The Journal of experimental medicine.

[13]  M. Andersen,et al.  Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. , 2004, Blood.

[14]  M. Greaves,et al.  Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Stirewalt.  Fine-tuning PU.1 , 2004, Nature Genetics.

[16]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[17]  N. Speck,et al.  Core-binding factors in hematopoiesis and immune function , 2004, Oncogene.

[18]  D. Levanon,et al.  Structure and regulated expression of mammalian RUNX genes , 2004, Oncogene.

[19]  Yoshiaki Ito.  Oncogenic potential of the RUNX gene family: ‘Overview’ , 2004, Oncogene.

[20]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[21]  S. Ogawa,et al.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis , 2004, Nature Medicine.

[22]  Tsukasa Okuda,et al.  VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development. , 2004, Blood.

[23]  S. Jhanwar,et al.  Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. , 2003, Blood.

[24]  Y. Hayashi,et al.  Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. , 2003, Blood.

[25]  T. Hoang,et al.  Translational control of SCL-isoform expression in hematopoietic lineage choice. , 2003, Genes & development.

[26]  C. Stocking,et al.  AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency , 2002, The Journal of experimental medicine.

[27]  C. von Kalle,et al.  Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[29]  A. Warren,et al.  Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1-ETO Translocation , 2002, Molecular and Cellular Biology.

[30]  D. Gilliland,et al.  Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.

[31]  S. Orkin,et al.  Transcriptional regulation of erythropoiesis: an affair involving multiple partners , 2002, Oncogene.

[32]  Elaine Dzierzak,et al.  Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. , 2002, Immunity.

[33]  J. Cyster,et al.  Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position , 2002, Nature.

[34]  T. Imamura,et al.  High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis. , 2002, Blood.

[35]  C. Chabannon,et al.  Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) cells impairs their ability to differentiate toward the B-lymphoid lineage. , 2001, Blood.

[36]  M. Taniwaki,et al.  Identification of an alternatively spliced form of the mouse AML1/RUNX1 gene transcript AML1c and its expression in early hematopoietic development. , 2001, Biochemical and biophysical research communications.

[37]  M. Kurokawa,et al.  Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. , 2000, Blood.

[38]  J. Downing,et al.  Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. , 2000, Immunity.

[39]  H. Takada,et al.  Immunophenotypic and functional characterization of CD33(+)CD34(+) cells in human cord blood of preterm neonates. , 2000, Experimental hematology.

[40]  K. Takenaka,et al.  Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. , 2000, Cancer research.

[41]  J. Dick,et al.  Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  J. Miyazaki,et al.  Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells , 2000, Nature Genetics.

[43]  J. Downing,et al.  Biological Characteristics of the Leukemia-Associated Transcriptional Factor AML1 Disclosed by Hematopoietic Rescue ofAML1-Deficient Embryonic Stem Cells by Using a Knock-in Strategy , 2000, Molecular and Cellular Biology.

[44]  H. Sather,et al.  Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Friedman.  Leukemogenesis by CBF oncoproteins , 1999, Leukemia.

[46]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[47]  D. An,et al.  Purification, amplification and characterization of a population of human erythroid progenitors , 1999, British journal of haematology.

[48]  T. Gu,et al.  Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. , 1999, Development.

[49]  W. Piacibello,et al.  Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. , 1999, Blood.

[50]  D Orlic,et al.  Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. , 1999, Blood.

[51]  B. Lord,et al.  CD34+AC133+ Cells Isolated from Cord Blood are Highly Enriched in Long‐Term Culture‐Initiating Cells, NOD/SCID‐Repopulating Cells and Dendritic Cell Progenitors , 1998, Stem cells.

[52]  M. Yamaguchi,et al.  Culture system for extensive production of CD19+IgM+ cells by human cord blood CD34+ progenitors , 1998, Leukemia.

[53]  S. Asano,et al.  A combination of stem cell factor and granulocyte colony‐stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS‐5 , 1998, European journal of immunology.

[54]  J. Kearney,et al.  AC133, a novel marker for human hematopoietic stem and progenitor cells. , 1997, Blood.

[55]  Y. Kanno,et al.  A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells , 1997, Molecular and cellular biology.

[56]  J. Dick,et al.  Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. , 1997, Blood.

[57]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[59]  E. Soeda,et al.  Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. , 1995, Nucleic acids research.

[60]  H. Hirai,et al.  An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. , 1995, The EMBO journal.

[61]  N. Copeland,et al.  PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials , 1994, Molecular and cellular biology.

[62]  M. Ohki,et al.  t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K. Nagata,et al.  Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. , 1989, Experimental hematology.

[64]  K. Mitani,et al.  Functional analysis of a dominant-negative DeltaETS TEL/ETV6 isoform. , 2004, Biochemical and biophysical research communications.

[65]  Kathryn L. Parsley,et al.  High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. , 2002, Human gene therapy.

[66]  A. Ryan,et al.  Rapid development of a quantitative-competitive (qc) RT-PCR assay using a composite primer approach. , 2002, Methods in molecular biology.